NOVA EYE MEDICAL LIMITED (EYE)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EYE - NOVA EYE MEDICAL LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.58
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.265

18 Apr
2024

0.015

OPEN

$0.27

6.00%

HIGH

$0.27

75,660

LOW

$0.26

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-9.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx17.0 M
Book Value Per Share xxxxxxxxxxxxxxx11.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-6.7 M
Net Profit Margin xxxxxxxxxxxxxxx-89.83 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-57.08 %
Return on Invested Capital xxxxxxxxxxxxxxx-54.74 %
Return on Assets xxxxxxxxxxxxxxx-45.66 %
Return on Equity xxxxxxxxxxxxxxx-57.08 %
Return on Total Capital xxxxxxxxxxxxxxx-41.53 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-7.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx7 M
Price To Book Value xxxxxxxxxxxxxxx2.17

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.8 M
Capex % of Sales xxxxxxxxxxxxxxx4.70 %
Cost of Goods Sold xxxxxxxxxxxxxxx16 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx13 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

EYE STOCK CHART